Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: A systematic review of randomised and nonrandomised controlled clinical trials

European Urology

Volumn 60, Issue 5, 2011, Pages 881-893

  Peinemann, Frank ^a   Grouven, Ulrich ^a,b   Bartel, Carmen ^a   Sauerland, Stefan ^a   Borchers, Holger ^c   Pinkawa, Michael ^d   Heidenreich, Axel ^d   Lange, Stefan ^a  

^a INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c General Hospital   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Localised prostate cancer; Low dose rate brachytherapy; Systematic review

Indexed keywords

BRACHYTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INTERMETHOD COMPARISON; INTESTINE FUNCTION; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCTIVE TOXICITY; REVIEW; SAFETY; SEXUAL FUNCTION; SYSTEMATIC REVIEW; URINARY TRACT FUNCTION; URINE INCONTINENCE;

BRACHYTHERAPY; CONTROLLED CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM INVASIVENESS; PATIENT SELECTION; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053335755     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.06.044     Document Type: Review

References (74)

1. Ebele JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of tumours of the urinary system and male genital organs. International Agency for Research on Cancer Web site. http://www.iarc.fr/en/publications/pdfs-online/pat- gen/bb7/bb7-cover.pdf.
2. Heidenreich A, Bolla M, Joniau S, et al. Guidelines on prostate cancer. European Association of Urology Web site. http://www.uroweb.org/gls/pdf/ Prostate%20Cancer%202010%20June%2017th.pdf.
3. Prostate cancer. Guideline for the management of clinically localized prostate cancer: 2007 update. American Urological Association Web site. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/ main-reports/proscan07/content.pdf.
4. R. Nath Overview of brachytherapy physics B.R. Thomadsen, M.R. Rivard, W. Butler, Brachytherapy physics ed. 2. 2005 Medical Physics Publishing Madison, WI
5. M.S. Soloway, M.A. Gorin, and D. Katkoori "Definitive therapy" for cancer: is our message clear? Eur Urol 58 2010 256 257
6. S.A. Rosenthal, N.H. Bittner, and D.C. Beyer American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer Int J Radiat Oncol Biol Phys 79 2011 335 341
7. J.M. Crook, A. Gomez-Iturriaga, and K. Wallace Comparison of health-related quality of life 5 years after SPIRIT (Surgical Prostatectomy [RP] versus Interstitial Radiation [BT] Intervention trial ACOSOG Z0070) Int J Radiat Oncol Biol Phys 78 Suppl 1 2010 S76
8. T.J. Wilt, R. MacDonald, I. Rutks, T.A. Shamliyan, B.C. Taylor, and R.L. Kane Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer Ann Intern Med 148 2008 435 448 (Pubitemid 351665443)
9. G. Koukourakis, N. Kelekis, V. Armonis, and V. Kouloulias Brachytherapy for prostate cancer: a systematic review Adv Urol 2009 327945
10. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med 6 2009 e1000097
11. IQWiG. Interstitial brachytherapy in localized prostate cancer; final report, commission N04-02 [in German; executive summary in English]. Institute for Quality and Efficiency in Health Care Web site. https://www.iqwig.de/ language-selector.986.en.html?tid=1196&phlex-override-command=element. Updated 2007 (17.01.200725.05.2010);15.
12. IQWiG. Interstitial brachytherapy in localized prostate cancer; rapid report, commission N10-01 [in German; executive summary in English]. Institute for Quality and Efficiency in Health Care Web site. https://www.iqwig.de/n10-01- interstitial-brachytherapy-in-localized.986.en.html?tid=1278. Updated 2011 (13.12.201023.01.2011);15.
13. ClinicalTrials.gov Web site. http://clinicaltrials.gov.
14. International Clinical Trials Registry Platform. World Health Organization Web site. http://apps.who.int/trialsearch.
15. ISRCTN. International Standard Randomised Controlled Trial Number Register, 2010. http://www.controlled-trials.com/isrctn.
16. UK Clinical Research Network. UKCRN Study Portfolio 2010. http://public.ukcrn.org.uk/search.
17. National Cancer Institute. Clinical Trials (PDQ) 2010. http://www.cancer.gov/clinicaltrials/search.
18. T.N. Eade, E.M. Horwitz, and K. Ruth A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or 125I permanent implant Int J Radiat Oncol Biol Phys 71 2008 338 345
19. M. Abdel-Wahab, I.M. Reis, and K. Hamilton Second primary cancer after radiotherapy for prostate cancer: a seer analysis of brachytherapy versus external beam radiotherapy Int J Radiat Oncol Biol Phys 72 2008 58 68
20. D.C. Beyer, and D.G. Brachman Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy Radiother Oncol 57 2000 263 267
21. H. Borchers, R. Kirschner-Hermanns, and B. Brehmer Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results BJU Int 94 2004 805 811 (Pubitemid 39472474)
22. E.B. Bradley, E.A. Bissonette, and D. Theodorescu Determinants of long-term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer BJU Int 94 2004 1003 1009 (Pubitemid 39577084)
23. M.J. Burdick, C.A. Reddy, and J. Ulchaker Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer Int J Radiat Oncol Biol Phys 73 2009 1439 1445
24. C. Buron, B. Le Vu, and J.M. Cosset Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study Int J Radiat Oncol Biol Phys 67 2007 812 822 (Pubitemid 46215887)
25. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974 (Pubitemid 28445094)
26. A.V. D'Amico, C.M. Tempany, and D. Schultz Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate Urology 62 2003 1063 1067 (Pubitemid 37510092)
27. J.W. Davis, D.A. Kuban, D.F. Lynch, and P.F. Schellhammer Quality of life after treatment for localized prostate cancer: differences based on treatment modality J Urol 166 2001 947 952 (Pubitemid 32750990)
28. S.P. Elliott, M.V. Meng, and E.P. Elkin Incidence of urethral stricture after primary treatment for prostate cancer: data from CaPSURE J Urol 178 2007 529 534 (Pubitemid 47030504)
29. M. Ferrer, J.F. Suarez, and F. Guedea Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer Int J Radiat Oncol Biol Phys 72 2008 421 432
30. C. Giberti, L. Chiono, F. Gallo, M. Schenone, and E. Gastaldi Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study World J Urol 27 2009 607 612
31. G.J. Huang, N. Sadetsky, and D.F. Penson Health related quality of life for men treated for localized prostate cancer with long-term followup J Urol 183 2010 2206 2212
32. R. Kirschner-Hermanns, B. Brehmer, and H. Borchers Do patients with urodynamically proven infravesical obstruction and detrusor overactivity have a higher risk for long-term bothersome symptoms after brachytherapy in comparison to patients treated with radical prostatectomy for localized prostate cancer? Curr Urol 2 2008 135 141
33. M. Kobuke, T. Saika, and Y. Nakanishi Prospective longitudinal comparative study of health-related quality of life in patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer Acta Med Okayama 63 2009 129 135
34. P.A. Kupelian, L. Potters, and D. Khuntia Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥ 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer Int J Radiat Oncol Biol Phys 58 2004 25 33 (Pubitemid 38010333)
35. W.R. Lee, M.C. Hall, R.P. McQuellon, L.D. Case, and D.L. McCullough A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy Int J Radiat Oncol Biol Phys 51 2001 614 623
36. J.B. Malcolm, M.D. Fabrizio, and B.B. Barone Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer J Urol 183 2010 1822 1828
37. A.M. Nieder, M.P. Porter, and M.S. Soloway Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study J Urol 180 2008 2005 2009
38. R.P. Ojha, L.A. Fischbach, Y. Zhou, M.J. Felini, K.P. Singh, and R. Thertulien Acute myeloid leukemia incidence following radiation therapy for localized or locally advanced prostate adenocarcinoma Cancer Epidemiol 34 2010 274 278
39. M.L. Pe, E.J. Trabulsi, and R. Kedika Effect of percentage of positive prostate biopsy cores on biochemical outcome in low-risk PCa treated with brachytherapy or 3D-CRT Urology 73 2009 1328 1334
40. T. Pickles, M. Keyes, and W.J. Morris Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis Int J Radiat Oncol Biol Phys 76 2010 43 49
41. M. Pinkawa, M.D. Piroth, and R. Holy Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer Radiother Oncol 96 2010 25 29
42. J. Sharkey, A. Cantor, and Z. Solc 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice Brachytherapy 4 2005 34 44 (Pubitemid 40292828)
43. D.P. Smith, M.T. King, and S. Egger Quality of life three years after diagnosis of localised prostate cancer: population based cohort study BMJ 339 2009 b4817
44. J.A. Talcott, J. Manola, and J.A. Clark Time course and predictors of symptoms after primary prostate cancer therapy J Clin Oncol 21 2003 3979 3986 (Pubitemid 46606212)
45. A.D. Vassil, E.S. Murphy, and C.A. Reddy Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation Urology 76 2010 1251 1257
46. W.W. Wong, S.A. Vora, and S.E. Schild Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy Cancer 115 2009 5596 5606
47. M.J. Zelefsky, K.E. Wallner, and C.C. Ling Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer J Clin Oncol 17 1999 517 522 (Pubitemid 29075237)
48. E.H. Zhou, R.J. Ellis, and E. Cherullo Radiotherapy and survival in prostate cancer patients: a population-based study Int J Radiat Oncol Biol Phys 73 2009 15 23
49. Wilt TJ, Shamliyan T, Taylor B, et al. Comparative effectiveness of therapies for clinically localized prostate cancer. Executive summary. Rockville, MD: AHRQ Agency for Healthcare Research and Quality; 2008.
50. Ollendorf DA, Hayes J, McMahon P, Kuba M, Tramontano A, Pearson SD. Brachytherapy/proton beam therapy for clinically localized, low-risk prostate cancer: final appraisal document 22.12.2008. Institute for Clinical and Economic Review Web site. http://www.icer-review.org/index.php/index.php?option=com- docman&task=doc-download&gid=42&Itemid=.
51. SEER Surveillance Epidemiology and End Results program. Stat fact sheets: prostate. National Cancer Institute Web site. http://seer.cancer.gov/statfacts/ html/prost.html.
52. J.M. Crook, A. Gomez-Iturriaga, and K. Wallace Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial J Clin Oncol 29 2011 362 368
53. J. Higham-Kessler, I.J. Kodner, and J.D. Keune Ethical counseling of an indecisive patient with low-risk prostate carcinoma: a case study Surgery 148 2010 1022 1025
54. T.L. Jang, J.E. Bekelman, and Y. Liu Physician visits prior to treatment for clinically localized prostate cancer Arch Intern Med 170 2010 440 450
55. R. Gillitzer, C. Hampel, and C. Thomas Bevorzugte Behandlungsoptionen des lokalisierten Prostatakarzinoms von deutschen Urologen und Radioonkologen bei eigener Erkrankung Urologe A 48 2009 399 407
56. J.H. Hayes, D.A. Ollendorf, and S.D. Pearson Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis JAMA 304 2010 2373 2380
57. K.M. Taylor, R.G. Margolese, and C.L. Soskolne Physicians' reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer N Engl J Med 310 1984 1363 1367 (Pubitemid 14149089)
58. G.A. Viani, E.J. Stefano, and S.L. Afonso Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials Int J Radiat Oncol Biol Phys 74 2009 1405 1418
59. G.L. Andriole Serum prostate-specific antigen: the most useful tumor marker J Clin Oncol 10 1992 1205 1207
60. M. Roach III, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
61. A.J. Stephenson, M.W. Kattan, and J.A. Eastham Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition J Clin Oncol 24 2006 3973 3978 (Pubitemid 46630746)
62. M.E. Nielsen, D.V. Makarov, E. Humphreys, L. Mangold, A.W. Partin, and P.C. Walsh Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion - "nadir + 2"? Urology 72 2008 389 393
63. E.M. Uchio, M. Aslan, C.K. Wells, J. Calderone, and J. Concato Impact of biochemical recurrence in prostate cancer among US veterans Arch Intern Med 170 2010 1390 1395
64. A. Thompson, M. Keyes, and T. Pickles Evaluating the Phoenix definition of biochemical failure after 125I prostate brachytherapy: can PSA kinetics distinguish PSA failures from PSA bounces? Int J Radiat Oncol Biol Phys 78 2010 415 421
65. M. Caloglu, and J. Ciezki Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon Urology 74 2009 1183 1190
66. Medizinischer Dienst des Spitzenverbandes Bund der Krankenkassen, Kompetenz Centrum Onkologie, Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, GKV-Spitzenverband. Prä ferenzbasierte Studie zur Evaluation der interstitiellen Brachytherapie beim lokal begrenzten Prostatakarzinom mit niedrigem Risiko; Studienkonzeption. G-BA Gemeinsamer Bundesausschuss Web site. http://www.g-ba.de/downloads/40-268-1103/ 2009-12-17-RMvV-Brachy-TrG.pdf. Updated 2009 (24.09.201009.11.2010).
67. Parulekar W. A phase III study of active surveillance therapy against radical treatment in patients diagnosed with favourable risk prostate cancer (START) [identifier NCT00499174 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00499174.
68. Bottomley D. SABRE 1: Surgery Against Brachytherapy; a Randomised Evaluation. Randomised controlled trial of brachytherapy versus radical prostatectomy in good risk prostate cancer: a feasibility study. ISRCTN Register Web site. http://www.controlled-trials.com/ISRCTN88144169.
69. D.G. Brachman, T. Thomas, J. Hilbe, and D.C. Beyer Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice Int J Radiat Oncol Biol Phys 48 2000 111 117 (Pubitemid 30488220)
70. T. Krupski, G.R. Petroni, E.A. Bissonette, and D. Theodorescu Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer Urology 55 2000 736 742
71. L. Potters, E.A. Klein, and M.W. Kattan Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation Radiother Oncol 71 2004 29 33 (Pubitemid 38452899)
72. J. Sharkey, A. Cantor, and Z. Solc Brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer Curr Urol Rep 3 2002 250 257
73. A.M. Andres, and A.S. Mato Choosing the optimal unconditioned test for comparing two independent proportions Comput Stat Data Anal 17 1994 555 574
74. J.F. Tierney, L.A. Stewart, D. Ghersi, S. Burdett, and M.R. Sydes Practical methods for incorporating summary time-to-event data into meta-analysis Trials 8 2007 16